|Bid||14.78 x 1100|
|Ask||16.75 x 1400|
|Day's Range||14.77 - 16.64|
|52 Week Range||14.77 - 20.48|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Fourteen Bay Area companies did IPOs in the first six months of 2018, nearly as many as the 15 that went public last year and the best first half since the recent high-water year of 2014, when 34 made their Wall Street debuts.
The local offerings are part of a boom in new biotech stocks that has seen more money raised in the first six months of 2018 than in all of last year.
SOUTH SAN FRANCISCO, Calif. , June 25, 2018 /PRNewswire/ -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics ...
Two more Bay Area life science IPOs are expected on Thursday, closely following two last week that hit their targets, and another one filed plans on Friday to join the parade. Meanwhile, the rapper Jay-Z, otherwise known as Shawn Carter, has filed paperwork to form a new venture firm based in San Francisco.
Five more venture-backed biotechnology companies were set to begin public trading Thursday, after each priced within or above its expected range.
SOUTH SAN FRANCISCO, Calif., June 20, 2018 /PRNewswire/ -- Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today that it has priced its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. The gross proceeds to Kezar, before deducting underwriting discounts, commissions and offering expenses, is expected to be approximately $75 million. All of the common stock is being offered by Kezar.
This week, there are a whopping eight biotech companies going public. Biotechnology isn’t an easy sector to grasp — it takes dedication to understand investment thesis, beginning the journey from drug development and ending at the drugstore. When it comes to investing in biotech stocks, the question is not just how well is this business run but whether their products fulfill a need in a growing industry … for biotechs, this can get complicated.